TWI233361B - Methods of preventing UVB-induced skin damage - Google Patents

Methods of preventing UVB-induced skin damage Download PDF

Info

Publication number
TWI233361B
TWI233361B TW091107218A TW91107218A TWI233361B TW I233361 B TWI233361 B TW I233361B TW 091107218 A TW091107218 A TW 091107218A TW 91107218 A TW91107218 A TW 91107218A TW I233361 B TWI233361 B TW I233361B
Authority
TW
Taiwan
Prior art keywords
tsp
skin
composition
cells
cell
Prior art date
Application number
TW091107218A
Other languages
English (en)
Chinese (zh)
Inventor
Michael J Detmar
Kiichiro Yano
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of TWI233361B publication Critical patent/TWI233361B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW091107218A 2001-04-13 2002-04-10 Methods of preventing UVB-induced skin damage TWI233361B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28387401P 2001-04-13 2001-04-13

Publications (1)

Publication Number Publication Date
TWI233361B true TWI233361B (en) 2005-06-01

Family

ID=23087934

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091107218A TWI233361B (en) 2001-04-13 2002-04-10 Methods of preventing UVB-induced skin damage

Country Status (8)

Country Link
US (1) US6712617B2 (https=)
EP (1) EP1377253A4 (https=)
JP (1) JP2004526758A (https=)
KR (2) KR20040021598A (https=)
CN (1) CN100340287C (https=)
CA (1) CA2446093A1 (https=)
TW (1) TWI233361B (https=)
WO (1) WO2002083088A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266706A1 (en) * 2002-11-05 2004-12-30 Muthiah Manoharan Cross-linked oligomeric compounds and their use in gene modulation
TWI312681B (en) * 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) * 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
US7238370B2 (en) * 2002-06-14 2007-07-03 Rosenberg E William Method and composition to prevent and treat photoaging of skin
EP1559429A4 (en) * 2002-06-25 2009-09-09 Shiseido Co Ltd AGAIN AGING AGING
CA2494536C (en) * 2002-07-31 2011-10-04 Mercian Corporation A 12-membered ring macrolide active substance
JP4459051B2 (ja) * 2002-07-31 2010-04-28 メルシャン株式会社 新規生理活性物質
US7458982B2 (en) 2002-10-04 2008-12-02 Photokinetix, Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
DE10254214A1 (de) * 2002-11-20 2004-06-09 Beiersdorf Ag Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz
BR0316746A (pt) * 2002-11-29 2005-10-18 Mercian Corp Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550)
US20050281761A1 (en) * 2004-04-01 2005-12-22 Michael Detmar Methods of preventing UVB-induced skin damage
US20050276762A1 (en) * 2004-06-15 2005-12-15 Tapas Das Topical compositions containing 5'-adenosine-diphosphate ribose
WO2006042114A1 (en) * 2004-10-06 2006-04-20 Cook, Inc. Emboli capturing device having a coil and method for capturing emboli
EP3340511B1 (en) 2004-10-12 2022-11-30 TQ Delta, LLC Resource sharing in a telecommunications enviroment
US9084734B2 (en) 2005-05-05 2015-07-21 Danisco Us Inc. Peptide personal care compositions and methods for their use
EP1938827A4 (en) * 2005-09-16 2010-07-21 Shiseido Co Ltd NEW HEMMER OF THE EXPRESSION OF VASCULAR ENDOTHEL GROWTH FACTOR
TWI428143B (zh) 2006-01-18 2014-03-01 Gen Hospital Corp 增加淋巴功能之方法
AU2007257055A1 (en) 2006-04-12 2007-12-13 Aware, Inc. Packet retransmission and memory sharing
WO2008005533A2 (en) * 2006-07-06 2008-01-10 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
WO2008020584A1 (en) * 2006-08-14 2008-02-21 Eisai R & D Management Co., Ltd. Stable lyophilized preparation
US7790887B2 (en) * 2007-01-29 2010-09-07 Eisai R&D Management Co., Ltd. Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same
CN101970012A (zh) 2007-09-14 2011-02-09 日东电工株式会社 药物载体
WO2011008904A1 (en) 2009-07-17 2011-01-20 Tabor Aaron T Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
EP2484359B1 (en) 2009-09-30 2018-07-25 Shiseido Company, Ltd. Heparanase activity inhibitor
US20240189397A1 (en) * 2019-12-24 2024-06-13 Juvena Therapeutics, Inc. Heparin-Associated Polypeptides and Uses Thereof
CN115379850A (zh) 2019-12-24 2022-11-22 裘美娜治疗公司 再生性多肽及其用途
WO2022271466A1 (en) 2021-06-21 2022-12-29 Juvena Therapeutics, Inc. Regenerative polypeptides and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025334A (en) * 1994-04-28 2000-02-15 Les Laboratoires Aeterna Inc. Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof
BR9809691A (pt) * 1997-05-27 2000-10-03 Sembiosys Genetics Inc Usos de substâncias de óleo
US6372234B1 (en) 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
WO1999026649A1 (en) * 1997-11-25 1999-06-03 Cornell Research Foundation, Inc. Methods and compositions for inhibiting hiv infectivity and blocking chemokine activity
EP1171151A4 (en) * 1999-03-31 2004-08-04 Gen Hospital Corp THROMBOSPONDIN-2 AND THEIR USE
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis

Also Published As

Publication number Publication date
US6712617B2 (en) 2004-03-30
KR20040021598A (ko) 2004-03-10
WO2002083088A1 (en) 2002-10-24
US20030008821A1 (en) 2003-01-09
JP2004526758A (ja) 2004-09-02
CN1512868A (zh) 2004-07-14
CN100340287C (zh) 2007-10-03
EP1377253A1 (en) 2004-01-07
EP1377253A4 (en) 2008-09-03
KR20080108366A (ko) 2008-12-12
CA2446093A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
TWI233361B (en) Methods of preventing UVB-induced skin damage
DE69821011T2 (de) Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen
Harrington et al. Influence of tumour size on uptake of111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model
ES2525476T3 (es) Derivados de alfa-MSH para el tratamiento de fotodermatosis
Wasterlain et al. Felbamate reduces hypoxic-ischemic brain damage in vivo
KR20080108530A (ko) 신경 쓰레드 단백질 기초 펩티드를 사용하여 암 위험 또는 발병을 예방 또는 감소시키는 방법
Tognetti et al. UVA‐1 phototherapy as adjuvant treatment for eosinophilic fasciitis: in vitro and in vivo functional characterization
JP2006521405A (ja) 発作回復におけるエリトロポイエチンの使用
US20050276765A1 (en) Preventing skin damage
Wang et al. Effects of delayed treatment with transforming growth factor-β soluble receptor in a three-dose bleomycin model of lung fibrosis in hamsters
EP1131087B1 (en) Methods of alleviating cancer symptoms
US10857199B2 (en) Compounds and methods for increasing hair growth
US8133491B1 (en) Compositions and methods for treatment of hyperplastic disorders
US20230364192A1 (en) Modulation of beta cell regeneration through gpr75 signaling
US20210213137A1 (en) Compositions to treat ultraviolet (uv)-induced skin injury
Desai et al. Noncanonical Nf-κB Activation by Icariin-Triggered CEBP-β/G-CSF Axis Confers Neuroprotection in Ischemic Optic Neuropathy
Esteban Pyrrole-imidazole polyamide-H promotes anti-inflammation during the acute phase of spinal cord injury
CN118806788A (zh) 活性氧在预防和/或治疗纤维化及与纤维化明确相关的疾病中的用途
CN121513016A (zh) 19-羟基蟾毒灵在制备治疗前列腺癌药物中的应用
AU2002254588A1 (en) Methods of Preventing UVB-Induced Skin Damage
JP2022532306A (ja) フェキサポチドトリフルタートを用いた下部尿路症状の治療効果を高める方法
HK1066173A (en) Methods of alleviating cancer symtoms
CN111588854A (zh) Trf2或其上调剂在制备治疗肌肉疾病的药物中的应用
Weller et al. Eosinophils from patients with blood eosinophilia express
Sinn et al. Albumin-Based Drug Delivery as Novel

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent